Horizon Therapeutics [HZNP] vs Johnson & Johnson [JNJ] Detailed Stock Comparison
Horizon Therapeutics
NASDAQ
Loading...
Johnson & Johnson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Horizon Therapeutics wins in 5 metrics, Johnson & Johnson wins in 12 metrics, with 0 ties. Johnson & Johnson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Horizon Therapeutics | Johnson & Johnson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 61.86 | 20.25 | Johnson & Johnson |
| Price-to-Book Ratio | 5.01 | 5.79 | Horizon Therapeutics |
| Debt-to-Equity Ratio | 0.48 | 64.69 | Horizon Therapeutics |
| PEG Ratio | -16.29 | 1.13 | Horizon Therapeutics |
| EV/EBITDA | 24.08 | 16.09 | Johnson & Johnson |
| Profit Margin (TTM) | 74.64% | 25.00% | Horizon Therapeutics |
| Operating Margin (TTM) | 16.83% | 28.91% | Johnson & Johnson |
| EBITDA Margin (TTM) | 16.83% | 28.91% | Johnson & Johnson |
| Return on Equity | 10.28% | 30.21% | Johnson & Johnson |
| Return on Assets (TTM) | 5.72% | 7.61% | Johnson & Johnson |
| Free Cash Flow (TTM) | N/A | $18.06B | N/A |
| Dividend Yield | N/A | 2.47% | N/A |
| 1-Year Return | -6.82% | 18.35% | Johnson & Johnson |
| Price-to-Sales Ratio (TTM) | 7.34 | 5.02 | Johnson & Johnson |
| Enterprise Value | $26.84B | $486.79B | Johnson & Johnson |
| EV/Revenue Ratio | 7.40 | 5.37 | Johnson & Johnson |
| Gross Profit Margin (TTM) | 76.72% | 67.87% | Horizon Therapeutics |
| Revenue per Share (TTM) | $16 | $38 | Johnson & Johnson |
| Earnings per Share (Diluted) | $2.22 | $9.33 | Johnson & Johnson |
| Beta (Stock Volatility) | N/A | 0.39 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Horizon Therapeutics vs Johnson & Johnson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Horizon Therapeutics | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Johnson & Johnson | 0.73% | 2.74% | 7.98% | 22.27% | 26.57% | 32.68% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Horizon Therapeutics | -6.82% | 74.04% | 9.84% | 176.66% | 176.66% | 176.66% |
| Johnson & Johnson | 18.35% | 16.19% | 29.02% | 94.50% | 200.58% | 199.97% |
News Based Sentiment: Horizon Therapeutics vs Johnson & Johnson
Horizon Therapeutics
News sentiment data is not available for Horizon Therapeutics at this time.
Johnson & Johnson
News based Sentiment: MIXED
October presented a mixed bag for Johnson & Johnson. While the company delivered strong Q2 results, raised its full-year guidance, and saw increased analyst and institutional confidence, a substantial legal setback related to baby powder claims introduced a significant risk. This combination of positive and negative developments makes it a noteworthy month for investors.
Performance & Financial Health Analysis: Horizon Therapeutics vs Johnson & Johnson
| Metric | HZNP | JNJ |
|---|---|---|
| Market Information | ||
| Market Cap | $26.63B | $456.84B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 19,134,206 | 8,800,060 |
| 90 Day Avg. Volume | 8,460,695 | 8,443,800 |
| Last Close | $116.30 | $191.08 |
| 52 Week Range | $116.30 - $116.34 | $140.68 - $192.05 |
| % from 52W High | -0.03% | -0.51% |
| All-Time High | $39.49 (Jul 20, 2015) | $192.10 (Oct 09, 2025) |
| % from All-Time High | 194.50% | -0.53% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.06% |
| Quarterly Earnings Growth | N/A | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.75% | 0.25% |
| Operating Margin (TTM) | 0.17% | 0.29% |
| Return on Equity (TTM) | 0.10% | 0.30% |
| Debt to Equity (MRQ) | 0.48 | 64.69 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $23.22 | $32.61 |
| Cash per Share (MRQ) | N/A | $7.84 |
| Operating Cash Flow (TTM) | $1.33B | $23.03B |
| Levered Free Cash Flow (TTM) | $1.81B | $11.08B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.47% |
| Last 12-Month Dividend | N/A | $3.72 |
Valuation & Enterprise Metrics Analysis: Horizon Therapeutics vs Johnson & Johnson
| Metric | HZNP | JNJ |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 61.86 | 20.25 |
| Forward P/E | 20.55 | 17.82 |
| PEG Ratio | -16.29 | 1.13 |
| Price to Sales (TTM) | 7.34 | 5.02 |
| Price to Book (MRQ) | 5.01 | 5.79 |
| Market Capitalization | ||
| Market Capitalization | $26.63B | $456.84B |
| Enterprise Value | $26.84B | $486.79B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.40 | 5.37 |
| Enterprise to EBITDA | 24.08 | 16.09 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.39 |
| Book Value per Share (MRQ) | $23.22 | $32.61 |
Financial Statements Comparison: Horizon Therapeutics vs Johnson & Johnson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HZNP | JNJ |
|---|---|---|
| Revenue/Sales | N/A | $23.74B |
| Cost of Goods Sold | N/A | $7.63B |
| Gross Profit | N/A | $16.12B |
| Research & Development | N/A | $3.52B |
| Operating Income (EBIT) | N/A | $6.81B |
| EBITDA | N/A | $9.21B |
| Pre-Tax Income | N/A | $6.49B |
| Income Tax | N/A | $954.00M |
| Net Income (Profit) | N/A | $5.54B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HZNP | JNJ |
|---|---|---|
| Cash & Equivalents | N/A | $38.47B |
| Total Current Assets | N/A | $71.55B |
| Total Current Liabilities | N/A | $56.90B |
| Long-Term Debt | N/A | $38.36B |
| Total Shareholders Equity | N/A | $78.11B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HZNP | JNJ |
|---|---|---|
| Operating Cash Flow | N/A | $6.35B |
| Capital Expenditures | N/A | $-795.00M |
| Free Cash Flow | N/A | $3.37B |
| Debt Repayment | N/A | $-2.87B |
| Common Stock Repurchase | N/A | $-2.13B |
Short Interest & Institutional Ownership Analysis
| Metric | HZNP | JNJ |
|---|---|---|
| Shares Short | N/A | 22.05M |
| Short Ratio | N/A | 2.84 |
| Short % of Float | N/A | 0.01% |
| Average Daily Volume (10 Day) | 19,134,206 | 8,800,060 |
| Average Daily Volume (90 Day) | 8,460,695 | 8,443,800 |
| Shares Outstanding | 229.00M | 2.41B |
| Float Shares | N/A | 2.40B |
| % Held by Insiders | N/A | 0.00% |
| % Held by Institutions | N/A | 0.74% |
Dividend Analysis & Yield Comparison: Horizon Therapeutics vs Johnson & Johnson
| Metric | HZNP | JNJ |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.72 |
| Last 12-Month Dividend Yield | N/A | 2.47% |
| 3-Year Avg Annual Dividend | N/A | $3.97 |
| 3-Year Avg Dividend Yield | N/A | 0.75% |
| 3-Year Total Dividends | N/A | $11.92 |
| Ex-Dividend Date | N/A | Feb 18, 2025 |